Literature DB >> 4029890

Hepatitis B virus DNA, HBeAg and delta infection during the course from acute to chronic hepatitis B virus infection.

K Krogsgaard, J Aldershvile, P Kryger, P Andersson, J O Nielsen, B G Hansson.   

Abstract

The presence of hepatitis B virus DNA in serum was determined in 57 unselected patients during the course from acute to chronic hepatitis B infection. Forty-six (81%) patients were hepatitis B virus DNA-positive in the first available serum sample. Generally, hepatitis B virus DNA was cleared before or at the same time as HBeAg, but in two patients (4%), hepatitis B virus DNA could be demonstrated after HBeAg clearance. One of the latter patients had hepatitis B virus DNA in the presence of anti-HBe. Both patients became hepatitis B virus DNA-negative. Seven of the hepatitis B virus DNA-positive patients received long-term treatment with prednisone, and three of them continued to be hepatitis B virus DNA positive for more than 10 years. Among the untreated patients hepatitis B virus DNA could be detected for up to 7 years, and 10 patients were hepatitis B virus DNA-positive for three years or more. Twenty-four patients (42%) showed serological signs of delta agent infection. Hepatitis B virus DNA clearance was observed in a significantly higher proportion (87%) of delta-infected patients as compared to patients with no delta infection (45%) (p less than 0.05). In addition patients with delta infection had a significantly increased hepatitis B virus DNA clearance rate as compared to patients without delta markers in their serum (p less than 0.01). In one (8%) delta-infected patient, hepatitis B virus DNA clearance was followed by a fall in transaminases into the normal range as opposed to results in 86% of patients with pure hepatitis B (p less than 0.002).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029890     DOI: 10.1002/hep.1840050512

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

Review 1.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

2.  Differential effect of chronic hepatitis D virus infection on intrahepatic expression of hepatitis B viral antigen.

Authors:  J Y Lau; B C Portmann; G J Alexander; R Williams
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

3.  Pattern and duration of HBV DNA seropositivity in acute hepatitis B.

Authors:  J R Wood; H F Taswell; A J Czaja; D Rabe
Journal:  Dig Dis Sci       Date:  1988-04       Impact factor: 3.199

4.  Tissue culture system for infection with human hepatitis delta virus.

Authors:  C Sureau; J R Jacob; J W Eichberg; R E Lanford
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Assay of hepatitis B virus genome titers in sera of infected subjects.

Authors:  E Zyzik; W H Gerlich; A Uy; H Köchel; R Thomssen
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

6.  Correlation of hepatitis B virus, hepatitis D virus and human immunodeficiency virus type I infection markers in hepatitis B surface antigen positive haemophiliacs and patients without haemophilia with clinical and histopathological outcome of hepatitis.

Authors:  N Wagner; H W Rotthauwe; M Becker; H P Dienes; T Mertens; H J Födisch; H H Brackmann
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

7.  Expression of intrahepatic hepatitis D viral antigen in chronic hepatitis D virus infection.

Authors:  J Y Lau; L J Hansen; V G Bain; K Chaggar; H M Smith; B C Portman; D Vergani; G J Alexander; R Williams
Journal:  J Clin Pathol       Date:  1991-07       Impact factor: 3.411

8.  Cloned hepatitis delta virus cDNA is infectious in the chimpanzee.

Authors:  C Sureau; J Taylor; M Chao; J W Eichberg; R E Lanford
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Evaluation of the pre-S (pre-S(1)Ag/pre-S(2)Ab) system in hepatitis B virus infection.

Authors:  M I Galán; J Tomás; M C Bernal; F J Salmerón; M C Maroto
Journal:  J Clin Pathol       Date:  1991-01       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.